BioNJ Presents 2nd Annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership to Genmab CEO, Lisa N. Drakeman, Ph.D.

TRENTON (January 22, 2009) — BioNJ, New Jersey’s trade association for bioscience companies, announced today that the second annual Dr. Sol J. Barer Award for Vision, Innovation and Leadership had been awarded to Lisa N. Drakeman, Ph.D., who is Chief Executive Officer of Genmab of Princeton, NJ.

Named for Sol J. Barer, Ph.D., the Chairman and Chief Executive Officer of Celgene Corporation of Summit, NJ, the award recognizes outstanding research and business leaders who have made and who continue to make significant contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.

Dr. Barer will present the award to Dr. Drakeman this evening during BioNJ’s Annual Meeting, Dinner and Awards program at the Hilton East Brunswick.

“Lisa Drakeman has been a guiding force in New Jerseys bioscience community and at BioNJ since the emergence of the industry in the early 1990s,” said Debbie Hart, President of BioNJ. “From those early days, it has been awe inspiring to watch as Lisa Drakeman has become an industry icon by establishing Genmab as a major factor in the industry while breaking every glass ceiling, not to mention records in financing and others. It has just been just amazing.”

Lisa N. Drakeman, Ph.D.
Dr. Drakeman has served as Genmab”s President and CEO since the company’s inception in 1999. Dr. Drakeman has over 18 years of experience working in the biotechnology industry, including establishing corporate partnerships with major pharmaceutical companies, managing clinical trials of monoclonal antibody-based products and developing government programs for financing biotechnology research.
At Genmab, she has set a number of financing records, including the largest private investment ever for a biotech company, the largest IPO ever by a European biotech company and the largest biotech licensing transaction worldwide with GlaxoSmithKline for ofatumumab, fully human, high-affinity antibody that is being developed under a worldwide co-development and commercialization agreement with GlaxoSmithKline (GSK) for the treatment of non-Hodgkin”s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, diffuse large B-cell lymphoma and remitting relapsing multiple sclerosis.

Under Dr. Drakeman’s leadership, Genmab received the 2007 Scrip Award for Biotech Company of the Year for its ability to bring new products closer to their first markets, raise capital, enter significant licensing agreements, and maintain strong management. Genmab has also received the James D. Watson Helix Award as the best international biotechnology company in 2004 for leadership in scientific innovation, company growth and corporate citizenship.

Dr. Drakeman has received a number of awards and honors including being named “Advocate of the Year” by the Biotechnology Industry Organization (BIO), “Industry Woman of the Year” by BioNJ in 1996, being inducted in the New Jersey High-Tech Hall of Fame in 2000 and one of “New Jersey”s Best 50 Women in Business” by NJBIZ in 2007. Dr. Drakeman serves as the Vice Chair of BioNJ. She previously served as a member of the faculty and administration at Princeton University and as Senior Vice President, Head of Business Development for Medarex, Inc.

She received a B.A. degree, from Mount Holyoke College, a M.A. degree, from Rutgers University, and M.A. and Ph.D. degrees, from Princeton University.

Sol J. Barer, Ph.D.
Dr. Barer has been CEO of Celgene, a global, integrated, biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases, since May 1, 2006 and Chairman since January 1, 2007. He was appointed President in 1993, Chief Operating Officer and Director in 1994 and is a member of the Executive Committee of the Board of Directors.

He founded the biotechnology group at Celanese that was subsequently spun out to form Celgene. Celgene is currently one of the world’s largest biotechnology companies with a market capitalization of over $20 Billion.

Dr. Barer is also on the Board of Trustees of Rutgers University, Board of Directors of PhRMA, serves as Secretary of the Board of Trustees of BioNJ, serves on the Board of Directors of Amicus Therapeutics and is on the Board of the Brooklyn College Foundation. He has previously served as a Commissioner of the NJ Commission on Science and Technology.

Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University.

In 2008, Dr. Barer was awarded the first Dr. Sol J. Barer Award for Vision, Innovation and Leadership. He also received the Lifetime Master Entrepreneur Award from Ernst & Young; The Hall of Distinguished Alumni Award of Rutgers University; the Corporate Vision Award from Gildas Club; and the Special Honoree Award from Community Hope. He has also received the Rutgers University Graduate School — 2007 Annual Distinguished Alumnus Award; the 2006 Winthrop-Sears Medal from the Chemists Club and the Chemical Heritage Foundation; the 2006 Corporate Leadership Award from The Multiple Myeloma Research Foundation; the Star Award of The Leukemia & Lymphoma Society; the 2005 Emerald Entrepreneurial and Excellence Award; the Albert Einstein Award in Life Sciences from Global Capital Associates and the Jerusalem Fund/Israel; the Insight Award from The Billy Foundation; and the DART/NYU Biotechnology Achievement Award in Applied Biotechnology.

About the Dr. Sol J. Barer Award for Vision, Innovation and Leadership

The Dr. Sol J. Barer Award for Vision, Innovation and Leadership was established by the BioNJ Board of Trustees in March 2008 as an annual award to recognize the outstanding research and business leaders who have made and continue to make significant contributions to the growth of the biosciences in New Jersey and around the world. The honoree is voted on by the BioNJ Board of Trustees from nominations taken from the Nominating Committee

About BioNJ
With 200 member companies, BioNJ is singularly focused on the growth and prosperity of New Jerseys bioscience cluster.

Founded in 1994 by New Jersey bioscience industry CEOs, BioNJ serves as the voice of bioscience companies located in New Jersey, seeks to advance their economic growth and development and works to encourage new and established companies from around the world to locate here. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.

# # #

CONTACT: Bill O’Donnell
BioNJ
Director of Public Affairs
O) 609-890-3185
C) 609-802-3091
bodonnell@BioNJ.org